Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹77 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Hester Biosciences reported a strong Q3 FY26 with standalone revenue growing 12% YoY and PAT surging 140% YoY, driven by favorable product mix and cost discipline. The poultry healthcare division led growth with 32% YoY revenue increase, supported by deeper market penetration and distribution expansion. The animal healthcare division declined 38% due to delayed government immunization programs, expected to recover in Q4. Key regulatory milestone achieved with H9N2 avian influenza vaccine license, opening domestic and export opportunities. The fill-finish facility was capitalized, doubling drug product capacity. Management aims to reduce tender dependence and strengthen commercial and export markets. Risk: sustained margin improvement depends on product mix management and institutional order timing.
Colored figures show movement against the previous available record.
Guidance to track
- Government immunization programs for PPR and goatpox (LSD) are expected to commence from February 2026, improving animal health division momentum in Q4.
- The remaining capital work in progress (₹182 Cr) is expected to be capitalized in the coming months, adding capacity.
- Management assured year-on-year improvement in margins, though quarterly margins may vary due to product mix seasonality.
Risks flagged
- Management acknowledged that quarterly margins are influenced by product mix and cannot be guaranteed, though year-on-year improvement is targeted.
- Animal health division revenue declined 38% due to delayed PPR and goatpox programs; recovery depends on timely execution starting February 2026.
- Africa operations rely on multilateral funding and country-level rollout timelines, which can cause execution delays.
- Management noted Nepal operations are in a challenging phase and are evaluating measures for stability and sustainability.
Key quotes
- The bird flu attack in Kerala has nothing to do with these numbers. Neither does it show a spurt in sales which has caused this profitability.
- We are here to grow our poultry business as well as the AH business. That's all that we can say.
- Our strategic priorities remain clear: to reduce dependence on tender-driven revenues and deepen our presence across commercial and export markets.
Research modules